Screener
CG Oncology CGON Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's cash & equivalents?
- CG Oncology (CGON) reported cash & equivalents of $19.64M in Q2 2026.
- How has CG Oncology's cash & equivalents changed year-over-year?
- CG Oncology's cash & equivalents increased by 34.3% year-over-year, from $14.62M to $19.64M.
- What is the long-term trend for CG Oncology's cash & equivalents?
- Over 2 years (2023 to 2025), CG Oncology's cash & equivalents has grown at a 98.3% compound annual growth rate (CAGR), from $8.27M to $32.49M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about CG Oncology's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude